Trial Profile
A phase I study to evaluate the safety and efficacy of LV305 combined with KEYTRUDA (pembrolizumab) in patients with melanoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Aug 2015
Price :
$35
*
At a glance
- Drugs LV 305 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 13 Aug 2015 New trial record